Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers (SnS)

This double-blind, randomised, factorial-design trial (n=120) will investigate the interaction effects between psilocybin (25 mg, oral) and the context of its administration in healthy volunteers with lower-than-average mental well-being.

The study, led by Dr Robin Carhart-Harris at the University of California, San Francisco, will employ a 2×2 factorial design to explore how different contextual factors (‘set and setting’) modulate the acute and post-acute effects of psilocybin.

Participants will be randomly assigned to receive either psilocybin or placebo in one of two distinct environmental conditions. The primary outcomes include changes in psychological well-being, measured by the Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS), emotional breakthrough, and the quality of the acute psychedelic experience. Secondary measures will include neuroimaging and electroencephalography (EEG) assessments to examine brain activity patterns. The study is expected to run from October 2024 to November 2028.

Topic Healthy Subjects
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of California San Francisco
At UCSF, there are two research teams dedicated to the study of psychedelics; the Neuroscape Psychedelic Division and the Translational Psychedelic Research Program.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.